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Purpose: To study the effect of AED exposure on head circumference in the newborn.
Methods: Data on all Swedish singletons births between 1995 and 2005, over 900,000 births, were
obtained from the Swedish Medical Birth Registry. The effects of AEDs on birth-weight-adjusted mean
head circumference (bw-adj-HC) were estimated by comparison with data from all births in an analysis
which was adjusted for year of birth, maternal age, parity, maternal smoking, and maternal body mass
index.
Results: A signiﬁcant reduction of mean bw-adj-HC was seen after both carbamazepine (CBZ) (standard
deviation scores (SDS) = 0.15, p < 0.001) and valproic acid (VPA) (SDS = 0.10, p = 0.04) in monotherapy.
No effect on mean bw-adj-HC was seen for phenytoin, clonazepam, lamotrigine and gabapentin. There
was a signiﬁcant increase in the occurrence of microcephaly (bw-adj-HC smaller than 2 SD below the
mean) after any AED polytherapy (OR = 2.85, 95% CI: 1.74–4.78) but not after AED monotherapy or
monotherapy with CBZ or VPA. CBZ or VPA was taken by 71% of the pregnant mothers on AED, and the
usage increased over time.
Conclusions: CBZ and VPA in monotherapy during pregnancy reduce mean bw-adj-HC. AED polytherapy
increases the rate of microcephaly but no signiﬁcant effect is seen of AED monotherapy. The possible
signiﬁcance for the further development of the child is uncertain but should be explored.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Teratogenic effects of antiepileptic drugs (AEDs) are well
known.1–4 Approximately 0.3% of all pregnant women have
epilepsy and is in need of a balanced AED treatment.5 To optimize
AED treatment regimens, good characterization of risks is required
not only for malformations but also for effects on fetal growth. To
date, most attention regarding intrauterine effect of anticonvul-
sants has been given to the malformations. However, Hvas et al.
showed that newborns of women with drug treated epilepsy had
lower birth weight, length, and head circumference (HC) but
normal gestational age compared to newborns of women without
epilepsy, and that none of these negative effects was present in
cases of untreated maternal epilepsy.6 Also, a few other studies
reported a decrease in body dimensions, especially a reduced HC,
after AED exposure in utero, where polytherapy often showed
stronger growth reduction effect than monotherapy did.7–9 Of the
‘‘old generation’’ AEDs, phenobarbital, phenytoin, primidone,
ethosuximide, carbamazepine (CBZ), clonazepam and valproic* Corresponding author. Tel.: +46 8 5177 6524; fax: +46 8 5177 3909.
E-mail address: catharina.lavebratt@ki.se (C. Lavebratt).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.09.002acid/valproat (VPA), some have been studied regarding effect on
fetal growth in small samples. To the ‘‘new generation’’ of AEDs
belong drugs introduced in the 1990 s and later, including
vigabatrin, lamotrigine, gabapentin, felbamate, oxcarbazepine,
topiramate, levetiracetam, pregabalin, zonizamide and clobazam.
CBZ and VPA are still the most commonly used AEDs in most
developed countries.
An AED-induced effect on fetal head growth has been found
primarily for CBZ. Hiilesmaa et al. studied 133 Finnish children
exposed to AEDs in utero and showed that CBZ alone, and in
polytherapy with phenobarbital, was associated with fetal head
growth retardation.8 In a Europeanmaterial of 577 infants exposed
to AEDs it was found that VPA treatment was associated with a
doubling of the risk for major malformations, whereas CBZ had
negative effects on body weight, length and HC at birth.7 On the
contrary, Battino et al. found a lower risk for small HC after
exposure to CBZ compared to VPA and pentobarbital monothera-
pies among 315 newborns.10 Interestingly, there was a signiﬁcant
trend for lower effect over time of CBZ on HC in a Swedish
population-based studywith births from 1973 to 1997.9 Their data
were based on a material of 963 women on AED treatment where
HC and gestational age were reduced by CBZ, but neither
intrauterine growth, birth weight or body length was. Othervier Ltd. All rights reserved.
Table 1
Head circumference (HC) in 500g birth weight classes among all infants born.
Birth weight Number newborns HC, mean SD (cm)
300–999 953 24.32.7
1000–1499 2,039 27.61.9
1500–1999 4,261 30.21.5
2000–2499 16,211 32.11.3
2500–2999 87,762 33.41.2
3000–3499 281,025 34.41.1
3500–3999 323,923 35.31.1
4000–4499 147,461 36.11.2
4500–6700 37,104 37.01.2
Total 900,739
Table 2
Number of infants exposed to AEDs during singleton pregnancies, 1995–2005. Only
drugs available in Sweden.
Antiepileptic drug Number of exposed infants
Monotherapy Polytherapy
Phenobarbital 11 8
Primidone 6 4
Phenytoin 137 24
Fosphenytoin 0 0
Ethosuximide 7 15
Clonazepam 71 43
Clobazam 0 2
Carbamazepine 1094 128
Oxcarbazepine 10 6
Valproic acid 460 80
Vigabatrin 22 17
Lamotrigine 308 114
Felbamate 0 0
Topiramate 7 16
Gabapentin 56 13
Levetiracetam 5 8
Zonizamide 0 0
Pregabalin 0 0
Unknown sort 1 0
Total number 2195 231
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consequences on body dimensions were found.
With this investigation we have estimated the effect on head
growth of exposure in utero to the new AEDs lamotrigine and
gabapentin and the old AEDs phenytoin, clonazepam, CBZ and VPA.
The large size of our material made it possible to study risks that
were previously estimated based on few exposures. Further, we
studied changes in the use and effects of AED over time.
2. Materials and methods
2.1. AED effect on birth-weight-adjusted head circumference (bw-
adj-HC) in newborns after exposure in utero
We analyzed data from the Swedish Medical Birth Registry
(SMBR) in which all newborns in Sweden are registered (National
Board of Health). Information on maternal drug use was collected
from a structured interview made by a midwife at the ﬁrst
antenatal visit (usually around 10–12 gestational weeks). There-
after, prescriptions from the antenatal care system given after the
ﬁrst visit were recorded. In this study, a record any time during
pregnancy counted as use of antiepileptic drug. All infants born
1995–2005 where the mother reported use of AEDs were selected
(n = 2718). From this group the following numbers of newborns
were excluded: six with reported CNS malformation and 64 who
were twins or triplets, and 223 infantswithout known birthweight
or HC. The remaining group consisted of 2426 newborns, that is,
0.27% of all singleton infants with known birth weight and HC,
without knownCNSmalformations andwith a record from the ﬁrst
antenatal care visit (n = 900,739 comprising the population group
of comparison).
The population infants were grouped by birth weight in 500 g
intervals. For each birth weight group the mean and SD of HC were
calculated for all newborns for each stratum according to year of
birth, maternal age (2 classes: <35 years, 35 years), parity (2
classes: 1, >1), maternal smoking (3 classes: 0 or no answer, <10,
10 cigarettes per day), maternal body mass index (3 classes:
<19.8, 19.8  BMI < 26, 26 kg/m2).
2.1.1. Quantitative analysis
For each infant exposed to AED in utero, its HC deviation from
the mean HC of the infant’s birth weight group in the population
data, according to year of birth, maternal age, parity, smoking, and
BMI, was calculated and expressed as the number of standard
deviations (SDs) in that stratum, a standard deviation score (SDS).
The mean of these SDS among the exposed infants was compared
with zero in t tests using two-sided tests and the standard error of
the mean (SEM) for the SDS. The effect of exposure to AED on bw-
adj-HCwas determined for infants exposed to any AED and also for
infants exposed to some speciﬁc drugs individually, used in
monotherapy or polytherapy. Differences in effects between the
three periods 1995–1997, 1998–2001 and 2002–2005 were
studied using analysis of variance.
2.1.2. Dichotomous analysis
We also estimated the impact of AED exposure on the
occurrence of microcephaly (bw-adj-HC smaller than 2 SD below
the expectedmean)with aMantel–Haenszel analysis, adjusting for
the same confounders as above and using Miettinen´s method to
estimate approximative 95% CI.
2.2. Association between mothers’ AED treatment during pregnancy
and their own bw-adj-HC at birth
Among the mothers to the 2426 newborns exposed in utero to
AED in 1995–2005, 1017 were born after 1973 and none after1988. Of those, 862 had their own birth recorded in SMBR and
for 850 of those there were data on birth weight and birth HC.
The control population consisted of all now living women born
1973–1988 according to SMBR with data on birth weight and
HC. The control population of women was grouped by birth
weight in 500 g intervals. For each birth weight group the mean
and SD of the womens’ birth HC were calculated for each
stratum according to year of birth. For each woman treated with
AED, her birth HC deviation from the mean birth weight speciﬁc
HC, expected from the population data according to year of birth
was determined and expressed as standard deviation score
(SDS). The mean of these SDS for those treated with AED was
compared with zero in t tests using two-sided tests and the SEM
for the SDS.
The Swedish ethical board at Karolinska Institutet approved the
study.
3. Results
Table 1 presents population data onmeanHCwith SD according
to birth weight class.
The frequencies of the various antiepileptic drugs among
singleton pregnancies for the whole period are listed in Table 2.
Monotherapies represented 90% of the cases (n = 2195). CBZ was
clearly the most commonly used drug (50% of the monotherapies),
Table 3
Effect of AEDs on mean birth-weight-adjusted HC, expressed as mean SDS from
population control material. Only drugs with at least 50 exposed singleton
pregnancies.
Antiepileptic drug Mono/poly SDS, mean SEM t p
Carbamazepine Mono 0.150.03 4.8 2106
Poly 0.170.09 1.7 0.09
Non-carbamazepine Mono 0.030.03 1.3 0.21
Poly 0.180.11 1.6 0.12
Valproic acid Mono 0.100.05 2.12 0.04
Poly 0.180.13 1.4 0.15
Phenytoin Mono 0.020.09 0.25 0.39
Clonazepam Mono 0.010.14 0.07 0.40
Lamotrigine Mono 0.0040.06 0.01 0.40
Poly 0.080.10 0.8 0.30
Gabapentin Mono 0.020.13 0.12 0.39
SDS, standard deviation score, i.e. the number of standard deviations that each AED-
exposed infant’s HC deviated from the mean HC in the population data in
corresponding stratum.
SDS, mean SEM, the mean and standard error of the mean of SDS scores among the
exposed infants.
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polytherapies, the majority (216) consisted of two AEDs.
3.1. Birth-weight-adjusted head circumference at birth (bw-adj-HC)
3.1.1. Quantitative analysis
A signiﬁcantly smaller mean bw-adj-HC was found among
newborns to mothers treated with AED compared to all births
during 1995–2005 (0.10 SDS units from mean of the population,
t = 4.8, p < 0.001). The effects on bw-adj-HC of the speciﬁc AEDs
used inmore than 50 cases were determined (Table 3). CBZ had the
strongest negative effect on bw-adj-HC. The effect was found to be
of the same order of magnitude for monotherapies (SDS = 0.15,
t = 4.8, p < 0.001) and polytherapies (SDS = 0.17, t = 1.9, p = 0.07).
VPA inmonotherapy also had a negative effect onmean bw-adj-HC
(SDS = 0.10, t = 2.1, p = 0.04). The other drugs analyzed; phenytoin,
clonazepam, lamotrigine and gabapentin in monotherapy showed
no effect on mean bw-adj-HC.
Analyses were performed in three groups of year of birth
separately: 1995–1997, 1998–2001, and 2002–2005. The number
of pregnancies reported with AED treatment increased over time
from 150 per year during 1995–1997, 217 in 1998–2001 to 276 in
2002–2005. An increase was also found for CBZ use in mono-
therapy: 85, 104 and 106 per year during the three periods. VPA
use also increased from 23 cases per year in 1995–1997 to 43 in
1998–2001 and 55 during 2002–2005. The negative effect of VPA
on mean bw-adj-HC showed a variation over time, being much
lower for 1998–2001 than in the other two periods (F = 4.9,
p = 0.01). However, the effect on mean bw-adj-HC of AEDs as a
group did not differ between the time periods (SDS = 0.11, 0.08 and
0.10, respectively) and neither did the effect of CBZ alone (F = 1.2,
p = 0.30).
3.1.2. Dichotomous analysis
Microcephaly (a bw-adj-HC smaller than 2 SD below the
expected mean) occurred in 2.6% of all infants and in 3.3% of the
infants exposed to AED in utero. The adjusted odds ratio (OR) for
having an infant with microcephaly after exposure to any AED in
polytherapy was 2.85 (95% CI: 1.74–4.78). However, in mono-
therapy the risk for microcephaly was increased neither after
any AED (OR = 1.17, 95% CI: 0.91–1.51), after CBZ alone
(OR = 1.26, 95% CI: 0.89–1.77) nor after VPA alone (OR = 1.14,
95% CI: 0.65–1.98).3.2. Mothers’ AED treatment during pregnancy and their own bw-adj-
HC at birth
Mothers on AED treatment during pregnancy in 1995–2005
born 1973–1988 had no different bw-adj-HC at birth compared to
the all women born 1973–1988 (SDS = 0.01  0.04).
4. Discussion
In this study we analyzed the effect on head circumference of
exposure in utero to AEDs during 1995–2005 in a large nation-wide
Swedish material. The analyses were adjusted for year of birth,
maternal age, parity, smoking, and body mass index. The most
commonly used monotherapies were CBZ, followed by VPA,
lamotrigine, and phenytoin. A signiﬁcant reduction of mean
birth-weight-adjusted head circumference (bw-adj-HC) was seen
after CBZ and VPA monotherapy. The effects of CBZ and VPA
corresponded to 0.2–0.4 cm. An increased risk ofmicrocephaly (HC
smaller than 2 SD below expected mean) was statistically
signiﬁcant after polytherapy but not after monotherapy or
monotherapy with CBZ or VPA. The possibility that the association
between AED exposure and bw-adj-HC of the newborn was due to
inheritance of small bw-adj-HC from the mother was tested. The
mean bw-adj-HC of themothers to the infants exposed to AEDwas
compared to that of all women born in the same year interval,
1973–1988, adjusting for year of birth. The mothers treated with
AED corresponded to almost half of the cohort of the AED-exposed
infants studied. Themothers treated with AED had similar bw-adj-
HC as the general female population suggesting that mothers’ bw-
adj-HC at birth was not a confounding factor.
CBZ was also previously shown to reduce body dimensions of
the newborn, primarily HC.8 However, a decline in the effect was
previously suggested in an earlier Swedish study.9 No decline in
effect of CBZ on bw-adj-HC over time was observed in the present
study spanning 7 additional years with more than double the
population size. VPA was in a previous small study shown to
reduce HC stronger than CBZ,10 however other small studies
(n = 62 and 30) showed no VPA effect on HC.7,11 None of the other
four AEDs studied, phenytoin, clonazepam, lamotrigine and
gabapentin, showed a signiﬁcant effect on mean bw-adj-HC.
Previous ﬁndings on effects of in utero exposure to the AEDs
studied here include the following. The effects on mean HC of CBZ
and VPA are similar, if anything higher for CBZ than VPA,7–10
whereas VPA but not CBZ has probable clinically relevant
malforming effect.12 Both CBZ and phenytoin monotherapies
possibly increase the risk for cleft palate,12 but phenytoin has not
been associated with microcephaly.13 Benzodiazepines usually
have a low malforming potential and small studies of clonazepam
in monotherapy (n = 43) had little information value.14,15 Few
studies on the fetal effect of gabapentin have been published. In a
study of the safety of gabapentin exposure in human pregnancy no
increased risk was found compared to the general population but
also this study had a low power due to the small number of
patients (n = 39).16 A recent study showed various malformations
of the brain in mice fetuses after gabapentin exposure in utero.17 A
dose-dependent malforming effect of lamotrigine has been
published,18 but this ﬁnding was not reproduced.19 Hence there
is insufﬁcient evidence to determine if there is a malforming effect
of clonazepam, gabapentin or lamotrigine.12
An increased risk for smaller HC by epilepsy per se has been
discussed, which could confound the ﬁndings of the effect of CBZ
and VPA on bw-adj-HC reported here. However, such confounding
by epilepsy indication is less likely in our study because four of the
six AEDs studied (phenytoin, clonazepam, lamotrigine and
gabapentin) showed very low mean SDS of bw-adj-HC, that is
estimated not to reach signiﬁcance using the CBZ monotherapy
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epilepsy. However, CBZ and VPA are not to a lower extent used for
non-epilepsy indications than the four AEDs with no effect on bw-
adj-HC. During recent years, notably VPA, lamotrigine and CBZ are
used as mood stabilizers in bipolar affective disorder, and also
other non-epilepsy diagnoses are sometimes treated with AEDs.
Moreover, Hvas et al. detected increased risk neither for lower
weight, length nor smaller HC at birth in infants to non-treated
epileptic mothers.6 Information on the speciﬁc indication for the
individual prescription of AED was not available for the studied
cohort.
To analyze difference in effect over time we divided the
material into three groups: 1995–1997, 1998–2001 and 2002–
2005. The use during pregnancy of CBZ was found to increase by
25% and VPA by 140%, between the ﬁrst and last period in spite of
recent reports on negative effects on newborns of these AEDs. The
effect of VPA on mean bw-adj-HC changed over time and was
lowest in the middle period (1998–2001) while no variation with
time was seen for CBZ or all AEDs as a group.
In utero exposure to AED polytherapy, and monotherapy with
VPA and phenytoin probably contribute to reduced cognitive
outcome (reviewed by Harden et al.12). Histopathologically,
apoptotic neurodegeneration has been found in the brain after
exposure of the young rodent to an AED (phenytoin, phenobarbital,
diazepam, benzodiazepine, vigabatrin, and valproate),20 which
hypothetically could impair cognitive function.21 In cell culture,
CBZ has been shown to induce mitotic arrest,22 and to inhibit
differentiation of embryonic stem cells into later stages, whereas
VPA was a potent inhibitor of all stages of mesodermal and
endodermal development.23 It is unknown if any of these
mechanisms contributes to the, on average, small reduction in
birth HC seen after in utero exposure to CBZ, VPA and AED
polytherapy.
The clinical signiﬁcance, at birth and in the developing child, of
the small reduction in birth HC associated with certain AED
exposures in utero is unknown. The high plasticity of the nervous
system at young age may compensate for disturbances.24
5. Conclusion
We have used a large nation-wide population-based material
and shown that there is an apparent difference between AED drugs
with respect to their effect on bw-adj-HC at birth. The strongest
effects were seen for CBZ and VPA. The effects were small, but were
statistically signiﬁcant and remained from 1995 to 2005. CBZ or
VPA were given to 71% of the cases, a prescription rate that
increased with 25% for CBZ and 140% for VPA over the last decade.
Phenytoin, clonazepam, lamotrigine and gabapentin had no certain
effect on bw-adj-HC. AED polytherapy increased the rate of
microcephaly.
Conﬂict of interest
None of the authors has any conﬂict of interest to disclose.
Acknowledgements
This work was supported by grants from the Swedish Research
Council-Medicine, NARSAD, Swedish Society of Medicine and
Karolinska Institutet Foundation. B.K. was supported by a grantfrom the Evy and Gunnar Sandberg Foundation. We like to express
our gratitude to Orvar Eeg-Olofsson and Inger O¨hman for helpful
discussions. We conﬁrm that we have read the journal’s position
on issues involved in ethical publication and afﬁrm that this report
is consistent with those guidelines.
References
1. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs and reproduc-
tive outcome: epidemiologic and experimental ﬁndings spanning three dec-
ades. 2. Human studies. Reprod Toxicol 1991;5:301–35.
2. Finnell RH, Dansky LV. Parental epilepsy, anticonvulsant drugs and reproduc-
tive outcome: epidemiologic and experimental ﬁndings spanning three dec-
ades. 1. Animal studies. Reprod Toxicol 1991;5:281–99.
3. Matalon S, Schechtman S, Goldzweig G, Orney A. The teratogenic effect of
carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9–
17.
4. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Seizure 2008;17:
166–71.
5. Morrell MJ. Epilepsy in women. Am Fam Physician 2002;66:1489–94.
6. Hvas CL, Henriksen TB, Ostergaard JR, DamM. Epilepsy and pregnancy: effect of
antiepileptic drugs and lifestyle on birthweight. BJOG 2000;107:896–902.
7. Bertollini R, Kallen B, Mastroiacovo P, Robert E. Anticonvulsant drugs in
monotherapy effect on the fetus. Eur J Epidemiol 1987;3:164–71.
8. Hiilesmaa VK, Teramo K, Granstrom ML, Bardy AH. Fetal head growth retarda-
tion associated with maternal antiepileptic drugs. Lancet 1981;2:165–7.
9. Wide K,Winbladh B, Tomson T, Kallen B. Body dimensions of infants exposed to
antiepileptic drugs in utero: observations spanning 25 years. Epilepsia
2000;41:854–61.
10. Battino D, Granata T, Binelli S, Caccamo ML, Canevini MP, Canger R, et al.
Intrauterine growth in the offspring of epileptic mothers. Acta Neurol Scand
1992;86:555–7.
11. Arulmozhi T, Dhanaraj M, Rangaraj R, Vengatesan A. Physical growth and
psychomotor development of infants exposed to antiepileptic drugs in utero.
Neurol India 2006;54:42–6. [discussion 47].
12. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al.
Management issues for women with epilepsy-focus on pregnancy (an evi-
dence-based review). II. Teratogenesis and perinatal outcomes: Report of the
Quality Standards Subcommittee and Therapeutics and Technology Subcom-
mittee of the American Academy of Neurology and the American Epilepsy
Society. Epilepsia 2009;50:1237–46.
13. Monson RR, Rosenberg L, Hartz SC, Shapiro S, Heinonen OP, Slone D. Diphe-
nylhydantoin and selected congenital malformations. N Engl J Med 1973;289:
1049–52.
14. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based
case-control teratologic study of nitrazepam, medazepam, toﬁsopam, alprazo-
lum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod
Biol 2002;101:1147–54.
15. Lin AE, Peller AJ,WestgateMN, Houde K, Franz A, Holmes LB. Clonazepamuse in
pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol
2004;70:534–6.
16. Montouris G. Gabapentin exposure in human pregnancy: results from the
Gabapentin Pregnancy Registry. Epilepsy Behav 2003;4:307–17.
17. Prakash. Prabhu LV, Rai R, Pai MM, Yadav SK, Madhyastha S, et al. Teratogenic
effects of the anticonvulsant gabapentin in mice. Singapore Med J 2008;49:47–
53.
18. Morrow JI, Russell A, Gutherie E, Parsons L, Robertson I, Waddell R, et al.
Malformation risks of antiepileptic drugs in pregnancy: a prospective study
from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry
2006;77:193–8.
19. Cunnington M, Ferber S, Quartey G, The International Lamotrigine Pregnancy
Registry Scientiﬁc Advisory Committee. Effect of dose on the frequency ofmajor
birth defects following fetal exposure to lamotrigine monotherapy in an
international observational study. Epilepsia 2007;48:1207–10.
20. Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, et al.
Antiepileptic drugs and apoptotic neurodegeneration in the developing brain.
Proc Natl Acad Sci USA 2002;99:15089–94.
21. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the
developing brain. Ann N Y Acad Sci 2003;993:103–14.
22. Pe´rez Martı´n JM, Ferna´ndez Freire P, Labrador V, Hazen MJ. Carbamazepine
induces mitotic arrest in mammalian Vero cells. Mutat Res 2008;637:124–33.
23. Murabe M, Yamauchi J, Fujiwara Y, Miyamoto Y, Hiroyama M, Sanbe A, et al.
Estimation of the embryotoxic effect of CBZ using an ES cell differentiation
system. Biochem Biophys Res Commun 2007;356:739–44.
24. JohnstonMV. Plasticity in the developing brain: implications for rehabilitation.
Dev Disabil Res Rev 2009;15:94–101.
